Current challenges in NF2 therapy {#S1}
=================================

Neurofibromatosis type 2 (NF2) is a dominantly inherited genetic condition with a birth prevalence of 1 in 25,000^[@R1]^. NF2 is characterized by bilateral vestibular schwannomas (VS), which are benign tumors composed of neoplastic Schwann cells that arise from the eighth cranial nerve, which transmits hearing and balance information from the ears to the brain. Although these vestibular schwannomas grow slowly, they usually lead to a significant or total hearing loss by young adulthood or middle age. The tumors can also compresses the brain stem, leading to headaches, difficulty swallowing, and other serious neurologic symptoms^[@R2]^. Standard approaches for the treatment of growing VS include surgical resection and radiation therapy (RT). While these tumors can be successfully removed or destroyed with surgery and radiation treatment, paradoxically, these therapeutic approaches can also cause hearing loss. For patients with sporadic VS who do not have NF2, RT is associated with long-term tumor control rates exceeding 95%. However, hearing preservation rates after radiation range from 50-80%^[@R3],[@R4]^. Post-RT outcomes for patients with NF2 are inferior to those for sporadic patients, with short-term local tumor control rates around 80-85% and hearing preservation rates less than 50%^[@R3]^. Thus, the identification of a novel adjunct therapy to enhance radiosensitivity while minimizing toxicity-related hearing loss in VS is urgently needed.

Recent advances in targeted therapy for NF2 {#S2}
===========================================

Several previous investigations have suggested that -- unlike other benign tumors -- vestibular schwannomas, like malignant tumors, are able to induce the formation of new blood vessels. Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are expressed in VS, and VEGF expression level positively correlates with schwannoma growth rate^[@R5]-[@R7]^. A 2009 New England Journal of Medicine study led by Scott Plotkin, MD, PhD, reported that treatment with bevacizumab, a humanized monoclonal antibody that specifically neutralizes VEGF-A, was associated with a reduction in the volume of most growing VS. More importantly, bevacizumab treatment improved hearing in 57% patients^[@R7]^. Limitations of anti-VEGF treatment -- the fact that not all patients responded, that hearing improvement was often transient and the effect of anti-VEGF on nerve function is not known, and that some patients could not tolerate long-term bevacizumab treatment -- indicated the need to better understand the mechanisms of anti-angiogenic therapy on the function of tumor-bearing nerves.

Rationally combining anti-VEGF therapy with radiation {#S3}
=====================================================

Anti-VEGF agents were originally developed to block tumor growth by inhibiting blood vessel formation^[@R8],[@R9]^. Bevacizumab has failed to improve survival benefit as a monotherapy in a number of tumors, but has been shown to confer survival benefit in combination with chemotherapy^[@R9]^. A potential explanation for the success of combined therapies is that bevacizumab "normalizes" the abnormal vasculature of tumors. It has been shown in many preclinical and clinical studies that anti-angiogenic therapy prunes tumor vessels and reverts the abnormal structure and function of the remaining vasculature toward a more normal state, abrogating its deleterious effects on the tumor microenvironment^[@R10]^. However, the normalization effect is transient -- leading to a "normalization window" -- during which the resulting vasculature is more normal, characterized by increased blood flow and improved delivery of concurrently administered anti-cancer drugs, as well as oxygen^[@R9]^. The addition of anti-angiogenic therapy to chemotherapy is now standard treatment for a variety of metastatic cancers including colorectal cancer and nonsquamous cell lung cancer.

Given the role of tissue oxygenation in tumor response to radiation, as well as the potential protective role of VEGF against endothelial cell apoptosis in response to radiation, several preclinical studies have demonstrated that anti-angiogenic treatment potentiates the effects of radiation therapy against various solid tumors established from cell lines in xenograft models ([Table 1](#T1){ref-type="table"}). To date, early-phase clinical trials have demonstrated promising response rates and tolerability of combining bevacizumab with radiation for the local control of various primary, recurrent, and metastatic tumors ([Table 2](#T2){ref-type="table"})^[@R11]-[@R14]^. These studies have found that some additional toxicities occur with the combination of bevacizumab, but common toxicities such as hypertension and proteinuria are generally easily managed while severe toxicities are rare. However, the reported response rate has varied, indicating the need for a rational pre-selection of patients for this combination treatment, as well as prospectively validated biomarkers of response^[@R12],[@R15]-[@R19]^.

Combining anti-VEGF treatment with radiation therapy achieves better tumor control and minimizes radiation-related neurological damage in NF2-related schwannoma models {#S4}
=======================================================================================================================================================================

Although there are many reports in the context of malignant cancers, little is known of the effect of combined anti-VEGF treatment with radiation therapy in benign tumors. Recent studies led by Lei Xu, MD, PhD, at Massachusetts General Hospital report that combining anti-VEGF treatment with radiation therapy improves the effectiveness of radiation treatment in NF2 related vestibular schwannoma models, and that the combination allows the use of a lower radiation dose to achieve the same degree of tumor control as a higher radiation dose without anti-VEGF therapy^[@R20]^. As a step further, this study shows that combining anti-VEGF treatment with radiation improves neurologic function by i) reducing the dose of radiation therapy and minimizing treatment-associated adverse effects, and ii) alleviating tissue edema, which may further improve neurologic function by decreasing muscle atrophy and increasing nerve regeneration^[@R20]^. This study provides compelling rationale and paves the road for testing combined anti-VEGF therapy with RT in NF2 related vestibular schwannomas. In preparation for future clinical studies with combined anti-angiogenic and RT, clinical studies of the therapeutic effects of anti-VEGF treatment on radiation-induced nerve damage need to be thoroughly examined. Furthermore, characterization of the schwannoma vasculature (including relative schwannoma vessel size and permeability, tumor contrast enhancement, edema-associated parameters from MRI), and biomarkers studies are needed to fully elucidate the normalization effect of bevacizumab in NF2 patients, and are needed before clinical studies with combined anti-angiogenic and RT can be designed.
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###### 

Preclinical studies of combined anti-angiogenic and radiation therapy.

  -------------------------------------------------------------------------------------
  Tumor                  Cell line   Result                           Reference
  ---------------------- ----------- -------------------------------- -----------------
  NF2 Schwannoma         HEI193\     Enhanced tumor inhibition\       ([@R20])
                         NF2^−/−^    Decreased dose of radiation\     
                                     Improved neurological function   

  Glioblastoma           U87         Enhanced tumor inhibition\       ([@R21]-[@R25])
                                     Decreased dose of radiation      

                         U251        Enhanced tumor inhibition\       ([@R24])
                                     Decreased dose of radiation      

  Head and neck cancer   SCC1        Enhanced tumor inhibition        ([@R26])

  Colorectal cancer      LS174T      Enhanced tumor inhibition\       ([@R21])
                                     Reduced radioresistance          

                         SW480       Enhanced tumor inhibition        ([@R27])

  Ovarian carcinoma      MA148       Enhanced tumor inhibition        ([@R28])

  Melanoma               B16F10      Enhanced tumor inhibition        ([@R28])

  Lung cancer            54A         Decreased dose of radiation      ([@R23])

                         H226        Enhanced tumor inhibition        ([@R26])

                         A549        Enhanced tumor inhibition\       ([@R29])
                                     Decreased dose of radiation      
  -------------------------------------------------------------------------------------

###### 

Clinical trials of combined anti-angiogenic and radiation therapy.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Tumor type                Phase   Number of\               Radiation dose\     Bevacizumab\   Outcome                   Reference           
                                    Patients                 /Fraction           Dose                                                         
  ------------------------- ------- ------------------------ ------------------- -------------- ------------------------- ------------------- ----------
  CNS Tumor                                                                                                                                   

  nGBM                      III     978                      60Gy/2Gy            10mg/kg        Median PFS: 10.7\         Median OS: 15.7\    ([@R30])
                                                                                                months                    months              

  nGBM                      III     921                      60Gy/2Gy            10mg/kg        Median PFS: 10.6\         Median OS: 16.8\    ([@R31])
                                                                                                months                    months              

  nGBM                      II      70                       60 Gy/30            10 mg/kg       PFS: 19.6%                OS: 13.6%           ([@R32])

  nGBM                      II      75                       59.4 Gy/33          10 mg/kg       PFS: 21.2%                OS: 14.2%           ([@R33])

  nGBM                      II      125                      50.4Gy/1.8Gy        10mg/kg        Median PFS: 13.8 months   1-year PFS: 63.1%   ([@R34])

  nGBM                      II      68                       60Gy/2Gy            10mg/kg        Median PFS: 11.3 months   Median OS: 13.9\    ([@R35])
                                                                                                                          months              

  nGBM                      II      48                       60Gy                10mg/kg        Median PFS: 9.2 months    Median OS: 13.2\    ([@R36])
                                                                                                                          months              

  rGBM                      I       25                       30 Gy/5             10 mg/kg       PFS: 12.5-16.5%           OS: 7.3-7.5%        ([@R37])

  rGBM                      I/II    15                       25Gy/5              10mg/kg        Median PFS: 3.9 months    Median OS: 14.4\    ([@R38])
                                                                                                                          months              

  Head and neck cancer                                                                                                                        

  HNSCC                     II      30                       56-70Gy/35          5 mg/kg        3-year PFS: 61.7%         3-year OS: 68.2%    ([@R39])

  HNSCC                     0       29                       9.5-71.5Gy/1.25Gy   10mg/kg        3-year PFS: 82%           3-year OS: 86%      ([@R40])

  HNSCC                     II      42                       70Gy/2.12Gy         15mg/kg        2-year PFS: 75.9%         2-year OS: 88%      ([@R41])

  HNSCC                     II      78                       70Gy/35             15mg/kg        2-year PFS: 75%           2-year OS: 88%      ([@R42])

  HNSCC                     II      30                       70Gy/35             15mg/kg        2-year PFS: 88.5%         2-year OS: 92.8%    ([@R43])

  Nasopharyngeal            II      46                       70Gy/33             15mg/kg        2-year PFS: 74.7%         2-year OS: 90.9%    ([@R44])

  Gastrointestinal cancer                                                                                                                     

  Esophagus                 II      62                       45Gy/1.8Gy          15mg/kg        pCR: 29%                                      ([@R45])

  Colorectal                II      32                       45Gy/1.8Gy          5mg/kg         pCR: 25%                  4-year OS: 91%      ([@R46])

  Rectal                    II      66                       50.4Gy/28           5mg/kg         1-year DFS: 85%\                              ([@R18])
                                                                                                2-year DFS: 97%                               

  Rectal                    I       11                       50.4 Gy/28          10-15 mg/kg    pCR: 18%                                      ([@R14])

  Rectal                    I/II    32                       50.4 Gy/28          5-10 mg/kg     pCR: 16%                                      ([@R13])

  Rectal                    II      25                       50.4 Gy/28          5 mg/kg        pCR: 32%                                      ([@R15])

  Rectal                    II      61                       50.4 Gy/28          5 mg/kg        pCR: 13%                                      ([@R47])

  Rectal                    II      42                       50.4 Gy/28          5 mg/kg        pCR: 18%                                      ([@R12])

  Rectal                    II      59                       45Gy/1.8Gy          5 mg/kg        pCR: 36%                                      ([@R48])

  Rectal                    II      91                       45Gy/25             5 mg/kg        pCR: 23.7%                                    ([@R49])

  Gynecological cancer                                                                                                                        

  Cervical                  II      60                       45Gy/25             10mg/kg        No treatment-related\                         ([@R50])
                                                                                                SAEs                                          

  Endometrial               II      34                       45Gy/25             5mg/kg         2-year PFS: 79.1%         2- year OS: 96.7%   ([@R51])

  Endometrial               II      15                       45Gy/25             10mg/kg        1-/3-year PFS: 80%/67%    1-/3-year OS:\      ([@R52])
                                                                                                                          93%/80%             

  Ovarian                   4       1-/3-year PFS: 80%/40%   1-/3-year OS:\                                                                   
                                                             100%/60%                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CNS: central nervous system, nGBM: newly diagnosed glioblastoma, rGBM: recurrent GBM, MG: malignant glioma, HNSCC: head and neck squamous cell carcinoma, RT: radiation therapy, PFS: progression-free survival, OS: overall survival, SAEs: serious adverse events, pCR: pathologic complete response, SRS: stereotactic radiosurgery
